A2 BIOTHERAPEUTICS
Live / Applied — Third extension granted (statement of use) (as of 13 Nov 2025)
What this means for you
Not registered yet, but its 15 Feb 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97796895
- Mark type
- Stylized text
- Filed
- 15 Feb 2023
- Published for opposition
- 26 Mar 2024
- Attorney of record
- Joi A. White
Goods and services
- Class 005 — Pharmaceuticals: Therapeutics in the nature of cells, proteins and protein complexes for the treatment and prevention of cancer, inflammation, and inflammatory diseases; biotherapeutics for the treatment and prevention of cancer, inflammation, and inflammatory diseases; medicines for the treatment and prevention of cancer, inflammation, and inflammatory diseases; pharmaceutical products for the treatment and prevention of cancer, inflammation, and inflammatory diseases; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutics and cell therapies in the nature of cells, proteins and protein complexes for the treatment of cancer, inflammation, and inflammatory diseases; engineered cell therapies in the nature of cells, proteins and protein complexes for medical purposes, namely, the treatment and prevention of cancer, inflammation and inflammatory diseases; engineered cell therapy platforms consisting of modified cells, cell receptors, proteins and protein complexes; cell platforms consisting of modified cells, cell receptors, proteins and protein complexes for the treatment and prevention of cancer, inflammation and inflammatory diseases; technology platforms for developing and engineering therapeutic cells, therapeutic proteins, therapeutic antibodies, therapeutics and cellular therapies for the treatment and prevention of cancer, inflammation, and inflammatory diseases; platform for autologous and allogeneic cell manufacturing; therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer, inflammation and inflammatory diseases; gene therapy products, namely, genetically engineered tissues for transplant purposes
Owner
- A2 Biotherapeutics, Inc., Agoura Hills, CA, US
- A2 Biotherapeutics, Inc., Agoura Hills, CA, US
Prosecution history
- 14 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 13 Nov 2025 — SOU EXTENSION 3 GRANTED
- 13 Nov 2025 — SOU EXTENSION 3 FILED
- 13 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 13 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 May 2025 — SOU EXTENSION 2 GRANTED
- 12 May 2025 — SOU EXTENSION 2 FILED
- 12 May 2025 — SOU TEAS EXTENSION RECEIVED
- 11 Dec 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Dec 2024 — SOU EXTENSION 1 GRANTED
- 12 Nov 2024 — SOU EXTENSION 1 FILED
- 12 Nov 2024 — SOU TEAS EXTENSION RECEIVED
- 21 May 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 26 Mar 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 26 Mar 2024 — PUBLISHED FOR OPPOSITION